Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omitting H2 antagonists versus famotidine in premedication for taxane hypersensitivity prophylaxis
TCTR20220913005Phase 3Completed
- Sponsor
- N/A
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of famotidine in cancer, sponsored by N/A. Started Sep 2022; status: completed.
02
Drugs
famotidine
03
Conditions
cancer
Beyond the preview
Go deeper on TCTR20220913005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220913005.